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Abstract
Background: Taurine depletion occurs in patients with end-stage chronic kidney disease (CKD). In contrast, in the
absence of CKD, plasma taurine is reported to increase following dietary L-glutamine supplementation. This study
tested the hypothesis that taurine biosynthesis decreases in a rat CKD model, but is rectified by L-glutamine
supplementation.
Methods: CKD was induced by partial nephrectomy in male Sprague-Dawley rats, followed 2 weeks later by 2
weeks of 12% w/w L-glutamine supplemented diet (designated NxT) or control diet (NxC). Sham-operated control
rats (S) received control diet.
Results: Taurine concentration in plasma, liver and skeletal muscle was not depleted, but steady-state urinary
taurine excretion (a measure of whole-body taurine biosynthesis) was strongly suppressed (28.3 ± 8.7 in NxC rats
versus 78.5 ± 7.6 μmol/24 h in S, P < 0.05), accompanied by reduced taurine clearance (NxC 0.14 ± 0.05 versus 0.70 ±
0.11 ml/min/Kg body weight in S, P < 0.05). Hepatic expression of mRNAs encoding key enzymes of taurine
biosynthesis (cysteine sulphinic acid decarboxylase (CSAD) and cysteine dioxygenase (CDO)) showed no statistically
significant response to CKD (mean relative expression of CSAD and CDO in NxC versus S was 0.91 ± 0.18 and 0.87 ±
0.14 respectively). Expression of CDO protein was also unaffected. However, CSAD protein decreased strongly in
NxC livers (45.0 ± 16.8% of that in S livers, P < 0.005). L-glutamine supplementation failed to rectify taurine
biosynthesis or CSAD protein expression, but worsened CKD (proteinuria in NxT 12.5 ± 1.2 versus 6.7 ± 1.5 mg/24 h
in NxC, P < 0.05).
Conclusion: In CKD, hepatic CSAD is depleted and taurine biosynthesis impaired. This is important in view of
taurine’s reported protective effect against cardio-vascular disease - the leading cause of death in human CKD.
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Background
There is considerable evidence that both acute kidney
injury and chronic kidney disease (CKD) lead in humans
and in animal models to secondary defects in distant or-
gans [1] including the liver [1–3]. The mechanism of this
coupling between kidney and liver is poorly understood,
but the chronic systemic inflammation that occurs in
CKD may exert effects on liver [3], and the stress-
activated MAP kinase P38 MAPK has been shown to
mediate inflammatory effects, and also promote further
release of inflammatory cytokines, in several models of
inflammatory liver injury [4–9]. It has been proposed
[10, 11] that the hepatic metabolic pathways that are af-
fected during CKD include the catabolism pathways of
the sulphur amino acids L-methionine and L-cysteine,
which normally culminate in generation of sulphurous
and sulphuric acid, and the sulphur amino acid taurine
[12–14]. An abnormally low concentration of taurine
has been reported in the blood plasma of end-stage
CKD patients receiving dialysis therapy [10, 11]. It has
been speculated that this arises from insufficiency of the
enzyme cysteine sulphinic acid decarboxylase (CSAD)
which plays a role in taurine biosynthesis by catalysing
the conversion of cysteine sulphinic acid (CSA) to hypo-
taurine which is the immediate precursor of taurine [13].
Another enzyme important here is cysteine dioxygenase
(CDO) upstream of CSAD which generates CSA, and is
regarded as a further site of metabolic control over
sulphur amino acid catabolism in liver [13]. An alterna-
tive pathway through the enzyme cysteamine (2-ami-
noethanethiol) dioxygenase also exists, but is regarded as
a minor contributor to taurine biosynthesis [15].
Taurine depletion in CKD is undesirable [10] in view
of taurine’s physiological importance [16], notably its re-
ported protective effect [17] against endothelial dysfunc-
tion and inflammatory cardio-vascular disease which is
the leading cause of death in patients with advanced
CKD [18]. It has been proposed that taurine depleted
patients with CKD could be treated by giving a taurine
supplement, for example in dialysis fluid [19] or as an
oral supplement [20]. However, such supplementation
has been reported to be hazardous, as it may be difficult
to control in CKD patients, leading to severe hypertauri-
naemia [20]. If the impaired taurine biosynthesis sug-
gested above is the cause of taurine depletion in CKD,
an alternative approach with less risk of accidental
hypertaurinaemia might be to rectify the impaired bio-
synthesis. The plasma concentration of taurine, both in
rats and humans with intact renal function, has been re-
ported to increase in response to dietary supplementa-
tion with L-glutamine [21] and the inward flux of
taurine into liver, kidneys and gut was also reported to
increase in the L-glutamine supplemented rats in that
study [21]. However, whether L-glutamine
supplementation can exert similar beneficial effects on
taurine in the presence of CKD is unknown. L-
glutamine is also a potentially attractive supplement to
test in CKD in view of its reported (but disputed [22])
anabolic effects, notably in skeletal muscle.
The aim of this study was therefore to investigate de-
fective taurine metabolism and its response to L-
glutamine supplementation in a rat partial nephrectomy
model of CKD. The hypothesis to be tested was that (a)
depletion of the enzyme CSAD occurs in the liver of
CKD rats compared with sham operated animals with
intact renal function, and (b) that dietary L-glutamine
supplementation rectifies the resulting defect in taurine
metabolism.
Methods
Rat partial nephrectomy (Nx) model of CKD
All surgical and experimental procedures were per-
formed subject to project licence reference PPL 80/2348
under the Animals (Scientific Procedures) Act (United
Kingdom, 1986), and were approved by the University of
Leicester Animal Welfare and Ethical Review Body.
The rat model of CKD (designated “Nx”) was estab-
lished in 250 g male Sprague-Dawley rats using a one-
stage surgical procedure as described previously [23]. All
animals were obtained from Charles River Laboratories,
Kent, UK. Briefly, rats were anaesthetised (3.5% isoflur-
ane in oxygen delivered at 2 l per min), accompanied by
sub-cutaneous administration of Rimadyl (Carpofen) 4
mg/Kg body weight) for post-operative analgesia. Anaes-
thesia was maintained during surgery using 2.5% isoflur-
ane in oxygen at 1 l/min. The foot withdrawal reflex was
tested to confirm anaesthesia. A 2 cm mid-line abdom-
inal incision was made just below the sternum, and the
left kidney was exposed and decapsulated, followed by
clamping of the vasculature in the stem of the kidney
with a 6mm aneurysm clip. Approximately half (~ 0.4 g)
of the kidney was excised (mainly from the cortex). Fol-
lowing removal of the clamping, bleeding was controlled
by applying Surgicel® haemostat (BUNZL Healthcare,
Coalville, UK) and the kidney remnant was repositioned
in the animal. The right kidney was then externalised
and decapsulated. Following ligation of the renal vascu-
lature with a Mersilk® (Vicryl 0) non-absorbable suture
(Johnson & Johnson, Maidenhead, Berkshire, UK) the
kidney was excised, and 5ml of 0.9% w/v sterile NaCl
was applied in the peritoneal cavity to compensate for
fluid loss during the surgery. An absorbable suture (Ethi-
con Vicryl® 3.0, Johnson & Johnson, Maidenhead, Berk-
shire, UK) was then used to close the abdominal muscle
layer, followed by closure of the skin with an Ethicon
Vicryl 5/0 suture (Johnson & Johnson, Maidenhead,
Berkshire, UK).
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Sham-operated control rats (designated “S”) were
treated as above, with exposure and decapsulation of
both kidneys, but no excision of tissue.
Study design
Following a 14 day post-surgery recovery period on con-
trol diet containing 14.38% crude protein and no taurine
(Rat and Mouse No 1 Maintenance diet expanded form
RM1(E) (Product Code 801002, Special Diets Services,
Essex, UK) with water ad libitum, rats were assigned for
a 14 day period to three experimental groups (n = 8 in
each group) designated NxC (partially nephrectomised
CKD rats receiving control diet), NxT (partially nephrec-
tomised CKD rats receiving test diet supplemented with
L-glutamine), and S (sham-operated control animals re-
ceiving control diet).
Test diet
Animals in the NxT group received the control diet
above supplemented with 12% L-glutamine by weight
[21]. In the previously reported study [21], an isocaloric
isonitrogenous supplement of control amino acids was
administered to the control rats that were not receiving
the L-glutamine supplement. This controlled for the ef-
fect of displacement of other nutrients in each Kg of diet
by the substantial mass of L-glutamine. However, in the
context of CKD, the nitrogen load associated with L-
glutamine supplementation may be detrimental by wors-
ening azotaemia. To allow the magnitude of this effect
of L-glutamine to be assessed in this CKD model, the
control CKD rats in Group NxC received control diet
without a supplement of control amino acids.
Throughout the 14 day experimental period, the rats
were housed individually in sets of 3 adjacent cages with
one NxC, one NxT and one S rat in each set. This was
done to minimise systematic effects of environmental
differences (e.g. small gradients in temperature, humidity
or lighting) across the facility in which the animals were
housed. The S rat in each set was pair fed with the ac-
companying NxC and NxT rats. Water was provided ad
libitum. On the last day of the experimental period the
rats were housed in metabolic cages to allow collection
of urine. At the end of the urine collection, the animals
were killed by exsanguination under terminal anaesthe-
sia. Blood was collected by aortic cannulation into
heparinised containers, and organs were removed,
weighed and frozen in liquid nitrogen.
Assessment of renal and liver function
Creatinine and urea in urine and plasma were assayed
colorimetrically using QuantiChrom® assay kits (Univer-
sal Biologicals, Cambridge, UK) according to the manu-
facturer’s instructions. Total urinary protein was
determined by precipitation with trichloro-acetic acid
followed by a colorimetric biuret assay [24]. Sulphate
(SO4
2−) excretion in urine was assayed (following re-
moval of urinary protein by precipitation with trichloro-
acetic acid), by addition of barium chloride and assay of
the resulting precipitate of barium sulphate by turbidim-
etry [25]. The liver function test enzyme alanine trans-
aminase (ALT) was assayed in plasma using a
colorimetric catalytic assay kit (Sigma-Aldrich, Gilling-
ham, UK) according to the manufacturer’s instructions.
Renal clearance of creatinine and taurine (expressed as







where Cu is the concentration of the solute in urine,
Cp is the concentration of the solute in plasma, Vu is the
average rate of urine production (in ml per minute) dur-
ing the urine collection period, and BW is the body
weight in Kg.
Assessment of body composition
Twenty mg samples of frozen liver were homogenised in
800 μl of ice-cold 0.3M perchloric acid and centrifuged
for 10 min at 4 °C and 3000 x g to sediment acid-
insoluble material which was assayed for total protein
[26] and total DNA [27]. Acid in the supernatant was
neutralised by vortexing with an equal volume of tri-n-
octylamine: 1,1,2-trichloro, trifluoro-ethane (22:78 vol/
vol) [28] and the top (aqueous) phase was removed and
stored at − 80 °C for subsequent analysis of free amino
acids. Free amino acids (including taurine) were sub-
jected to pre-column derivatization with o-
phthalaldehyde/3-mercaptopropionate/9-fluorenyl-
methylchloroformate, and the derivatives were separated
on an Agilent 1100 high-performance liquid chromato-
graph with a Zorbax Eclipse AAA (4.6 × 75mm, 3.5 μm)
column at 40 °C and quantified by post-column ultravio-
let detection. As skeletal muscle contains the body’s lar-
gest pool of lean tissue and of free amino acids
(including taurine), the same procedures were also ap-
plied to fast-twitch muscle (gastrocnemius) and slow-
twitch muscle (soleus) from each rat.
Amino acids in plasma were assayed following depro-
teinisation of 500 μl aliquots of plasma with 12.5 μl ali-
quots of 12M perchloric acid and neutralisation as
described above.
RNA extraction and qRT-PCR
Total RNA was extracted using TRIzol reagent (Invitro-
gen, Paisley, UK). Using 1 μg total RNA, cDNA was syn-
thesized using an AMV reverse transcription system
(Promega, Southampton, UK) according to the manufac-
turer’s instructions. Forward and reverse primer
Abbasian et al. BMC Nephrology          (2021) 22:250 Page 3 of 12
sequences used in this study are listed in Table 1. Real-
time PCR was performed using an Applied Biosystems
7500 Fast Real-Time PCR System (Thermo Fisher Scien-
tific, Loughborough, UK) using SYBR green PCR reagent
(Thermo Fisher Scientific, Loughborough, UK). Relative
amounts of mRNA were normalized to the correspond-
ing cyclophilin A signal for each sample, and relative ex-
pression is presented as (2-ΔΔCT) [29].
Immunoblotting
Cell lysates from each rat were subjected to SDS-PAGE
(30 μg protein per lane) followed by immunoblotting.
Immunoblotting was performed onto nitrocellulose
membranes (GE-Healthcare, Little Chalfont, UK)
followed by probing with primary antibodies against:
dually phosphorylated (P-Thr183/P-Tyr185) JNK2 (Pro-
mega, Southampton, UK); P38 MAPK (Cell Signaling
Technology, London, UK); phosphorylated (P-Thr180/P-
Tyr182) P38 MAPK (Cell Signaling Technology, London,
UK); β-Actin (Sigma-Aldrich, Gillingham, UK); CSAD
(custom antibody raised against peptide [C]-SLRGKKES
PDYSQRLS-amide) (Cambridge Research Biochemicals,
Billingham, UK); and CDO (a kind gift from Prof Martha
Stipanuk, Cornell University, New York, USA). Poly-
clonal Rabbit Anti-Mouse and Goat Anti-Rabbit Immu-
noglobulins/HRP (DakoCytomation (Agilent), Santa
Clara, USA) were used as secondary antibodies as appro-
priate and HRP-labelled proteins were detected by
chemiluminescence using ECL reagent (GE-Healthcare,
Little Chalfont, UK). Band intensities were quantified by
Image Lab Software v 5.2.1 (Bio-Rad) and data are pre-
sented as the ratio of the intensity for the protein of
interest/housekeeping protein expressed as a % of the
corresponding ratio under control conditions.
Statistical analysis
Analysis was performed using GraphPad Prism 8.1.2.
Normally distributed data are expressed as Mean ± SEM
and were analysed by 1-way repeated measures ANOVA
on the matched-fed groups, with Tukey’s range test post
hoc testing. Non-normally distributed data (determined
by the Shapiro-Wilk test) are expressed as Median (In-
ter-quartile Range) and were analysed by Friedman’s 1-
way ANOVA with Dunn’s multiple comparisons post
hoc testing.
Results
Confirmation of the CKD model
The animals in the 3 experimental groups were
matched for initial body weight and weight of food
consumed over the 14 day experimental period
(Table 2). Comparison of the partially nephrectomised
rats in Groups NxC and NxT with the sham-operated
rats in Group S showed moderately reduced glomeru-
lar filtration rate (GFR) (assessed from creatinine
clearance) and moderate azotaemia (elevated plasma
concentrations of urea and creatinine) (Table 2). Pro-
teinuria also occurred, but only in the L-glutamine
supplemented NxT animals (Table 2). In this short
14 day study, no significant cachexia was observed,
judged from Day 14 body weight, body weight gain
over the 14 days, skeletal muscle weights, heart weight
or liver weight (Table 2). Assessment of protein mass
in relation to cell number in these tissues, using the
total protein/DNA ratio, also failed to detect signifi-
cant cachexia (Table 2).
Confirmation of L-glutamine supplementation
Even though no significant increase in the concentration
of free L-glutamine or its catabolite L-glutamate was de-
tected in the plasma or tissues of the L-glutamine-
treated NxT rats compared with the NxC group
(Table 3), significantly enhanced urea excretion was ob-
served in the urine of the NxT rats (Table 2) and meas-
urement of urine volume showed significant diuresis in
the NxT group (Table 2). No significant anabolic effect
of L-glutamine was observed, judged from Day 14 body
weight, 14 day body weight gain, skeletal muscle weights,
heart weight, liver weight or total protein/DNA ratio in
these tissues (Table 2). The nitrogen load accompanying
this L-glutamine supplement also resulted in apparent
worsening of azotaemia (plasma urea in Table 2) al-
though this fell short of statistical significance (P = 0.064
versus NxC). No statistically significant difference in re-
sidual kidney mass was observed between the NxT
group and the NxC group (Table 2).
A small increase in the urinary excretion of free L-
glutamine and L-glutamate was detected in the NxT rats
compared with the NxC group (Table 3) but, when
expressed as moles of nitrogen per 24 h, this increase
was only about 0.1% of the corresponding increase in
urinary urea nitrogen (Table 2).
Table 1 Primers used for qRT-PCR
Gene Primer sequence
CSAD Forward 5′ – 3′ AGATGATCCCTGAGGATCTG
Reverse 5′ – 3′ TGGATCCCATCCAGGAGATG
CDO Forward 5′ – 3′ GACTGGCCTGACAAGAAATC
Reverse 5′ – 3’ TACAAGTGAAGGCTCACAGC
TauT (SLC6A6) Forward 5′ – 3’ TCTTCATTGCCATCGTGTGC
Reverse 5′ – 3’ AGGCATACACCACTAGCTGC
GAT2 (SLC6A13) Forward 5′ – 3’ GAAGAACCGGAGGGAGATTC
Reverse 5′ – 3’ GAGAACAGGAAGGTTGCCAG
Cyclophilin A Forward 5′ – 3’ CACCGTGTTCTTCGACATC
Reverse 5′ – 3’ TGCTGTCTTTGGAACTTTGTC
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Effect of the CKD model on taurine and sulphate
Even though the diet fed to all three experimental
groups in this study contained no taurine, a significant
rate of urinary taurine excretion was detected in all of
the rats (Table 3). Comparison of this rate in the NxC
CKD group with the control rate in sham operated
group S, revealed a significant 64% fall in this taurine ex-
cretion rate in CKD and the urinary taurine / SO4
2− ra-
tio was also significantly decreased by 64% in the NxC
group compared with the S group (Table 3). The total
rate of sulphur excretion (taurine plus SO4
2−) was 23%
lower in the NxC group compared with the S group
(Table 3). Mean total taurine plus SO4
2− excretion rate
was also 11% lower in the NxT group than in the NxC
group (Table 3).
In spite of the significant decline in the steady-state
rate of appearance of taurine in the urine in the CKD
rats (suggesting impaired taurine biosynthesis - see
Discussion), there was no corresponding fall in the
concentration of taurine in plasma, in liver or in
muscle (Table 3). When the plasma taurine concen-
tration and the rate of urinary taurine excretion were
used to calculate taurine clearance (Table 3), this was
found to be 81% lower in the NxC and NxT groups
of CKD animals compared with the sham-operated
control rats.
Table 2 Characterisation of the CKD model
Sham-operated, on Control
diet, S (n = 8)
Partial nephrectomy, on Control
diet, NxC (n = 8)
Partial nephrectomy, on Test
diet, NxT (n = 8)
Body composition
Body weight (Day minus 14) (g) 313.0 ± 14.5 308.9 ± 14.8 307.1 ± 15.1
Body weight (Day 1) (g) 335.6 ± 15.9 305.3 ± 13.2* 305.3 ± 13.7
Body weight (Day 14) (g) 374.0 ± 13.4 345.8 ± 12.2* 333.0 ± 12.8*
Body weight gain over days 1–14 (g) 38.4 ± 5.6 40.5 ± 5.0 27.7 ± 4.2|
Food consumed over days 1–14 (g) 317.5 ± 12.3 320.0 ± 12.6 312.7 ± 11.1
Gastrocnemius (mean of left & right)
Wet weight (g) 2.43 ± 0.08 2.25 ± 0.07 2.16 ± 0.12
Protein (μg per μg of DNA) 142 (121–182) 140 (111–164) 184 (117–281)
Soleus (mean of left & right)
Wet weight (g) 0.171 ± 0.013 0.163 ± 0.006 0.180 ± 0.023
Protein (μg per μg of DNA) 62 (50–71) 58 (50–76) 59 (43–65)
Heart
Wet weight (g) 1.237 ± 0.054 1.109 ± 0.042 1.192 ± 0.045
Protein (μg per μg of DNA) 139 (67–223) 120 (46–197) 137 (72–457)
Liver
Wet weight (g) 12.27 ± 0.88 10.55 ± 0.29 11.28 ± 0.63
Protein (μg per μg of DNA) 35 (32–42) 35 (26–85) 30 (25–61)
Left kidney
Wet weight (g) 1.217 ± 0.041 1.268 ± 0.064 1.374 ± 0.099
Plasma parameters
Creatinine (μM) 38.44 ± 2.56 92.60 ± 7.95* 115.65 ± 29.06
Urea (mM) 4.36 ± 0.72 13.27 ± 1.05* 26.44 ± 4.23*¶
24 h Urinary excretion parameters
Creatinine (μmol/24 h) 77.18 ± 8.04 68.89 ± 9.17 63.67 ± 7.39
Urea (mmol/24 h) 9.72 ± 0.94 10.45 ± 1.56 25.11 ± 2.76*|
Total protein (mg/24 h) 6.46 ± 0.71 6.74 ± 1.50 12.49 ± 1.19*|
Total volume (ml/24 h) 14.64 ± 1.31 23.71 ± 1.94* 53.45 ± 4.57*|
Creatinine clearance (GFR) (ml/min/
Kg body weight)
4.06 ± 0.47 1.51 ± 0.17* 1.51 ± 0.35
Unless otherwise stated, all parameters refer to Day 14 (i.e. 28 days after surgery). Feeding of experimental diets was performed from Day 1 to Day 14. Data are
presented as Mean ± SEM or as Median (inter-quartile range). *P < 0.05 versus Sham; |P < 0.05 versus NxC ¶P = 0.064 versus NxC
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Measurements of L-methionine (Table 3) failed to de-
tect any reproducible changes in plasma, liver or muscle
in the NxC group compared with the S group that might
have contributed to downstream effects on taurine.
Similarly no significant changes in L-cysteine were ob-
served in plasma and in gastrocnemius.
Effect of CKD on liver
When liver lysates were probed by immunoblotting, a
tendency towards phospho-activation of the stress-
activated MAP kinases JNK and P38 was detected in the
CKD rats in the NxC group relative to the sham-
operated control rats (Fig. 1a, b). However this did not
Table 3 Effect of CKD and dietary L-glutamine supplementation on free amino acids and sulphate (SO4
2−)
Sham-operated, on Control
diet, S (n = 8)
Partial nephrectomy, on Control
diet, NxC (n = 8)
Partial nephrectomy, on Test
diet, NxT (n = 8)
Tissue parameters
Gastrocnemius (mean of left & right)
L-glutamine (μmol/g) 5.48 ± 1.00 6.23 ± 1.31 5.61 ± 0.87
L-glutamate (μmol/g) 1.20 ± 0.44 1.38 ± 0.36 1.51 ± 0.47
L-cysteine (nmol/g) 44 ± 14 31 ± 13 27 ± 15
L-methionine (nmol/g) 82 ± 34 98 ± 36 100 ± 27
Taurine (μmol/g) 16.4 ± 2.7 15.6 ± 2.1 14.8 ± 1.2
Soleus (mean of left and right)
L-glutamine (μmol/g) 12.0 ± 2.7 15.1 ± 4.5 18.1 ± 6.1
L-glutamate (μmol/g) 3.89 ± 1.25 5.51 ± 1.53 6.78 ± 1.75
L-cysteine (nmol/g) ND ND ND
L-methionine (nmol/g) 99 ± 30 96 ± 23 156 ± 53
Taurine (μmol/g) 25.9 ± 2.6 25.7 ± 1.7 25.2 ± 1.8
Liver
L-glutamine (μmol/g) 7.11 ± 1.04 8.10 ± 1.13 9.09 ± 1.98
L-glutamate (μmol/g) 2.70 ± 0.89 1.76 ± 0.54 2.29 ± 0.50
L-cysteine (nmol/g) ND ND ND
L-methionine (nmol/g) 139 ± 20 101 ± 16 208 ± 45
Taurine (μmol/g) 5.04 ± 1.51 8.21 ± 1.84 8.05 ± 1.71
Plasma parameters
L-glutamine (μM) 830 ± 63 1067 ± 163 902 ± 228
L-glutamate (μM) 92.6 ± 23.8 156.3 ± 36.9 174.0 ± 46.4
L-cysteine (μM) 29.9 ± 4.2 46.3 ± 11.6 41.0 ± 8.4
L-methionine (μM) 70.9 ± 18.1 94.1 ± 19.1 79.9 ± 15.8
Taurine (μM) 289 ± 93 486 ± 119 354 ± 135
24 h Urinary excretion parameters
L-glutamine (μmol/24 h) 0.42 ± 0.22 4.81 ± 2.43 17.88 ± 5.62*
L-glutamate (μmol/24 h) 2.52 ± 0.33 1.72 ± 0.56 4.63 ± 0.99|
Taurine (μmol/24 h) 78.48 ± 7.63 28.25 ± 8.65* 15.56 ± 3.67*
Sulphate (SO4




0.507 ± 0.054 0.181 ± 0.048* 0.138 ± 0.041*
Total taurine + sulphate (SO4
2
−) (μmol/24 h)
237.5 ± 14.0 183.4 ± 22.1* 163.4 ± 33.1*
Taurine clearance (ml/min/Kg
body weight)
0.703 ± 0.105 0.136 ± 0.053* 0.133 ± 0.068*
All parameters refer to Day 14 (i.e. 28 days after surgery). Feeding of experimental diets was performed from Day 1 to Day 14. Concentrations in tissue are
expressed as nmol or μmol/g wet weight. Data are presented as Mean ± SEM. *P < 0.05 versus Sham. |P < 0.05 versus NxC
ND Not detectable
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reach statistical significance (P = 0.072 for P-JNK; P =
0.278 for P-P38). Furthermore, assay of the liver function
test (LFT) enzyme alanine transaminase (ALT) in the
rats’ plasma detected no increase in the CKD animals
(Fig. 1c).
qRT-PCR detected strong expression in liver of
mRNAs encoding both CDO and CSAD, the two
principal enzymes that regulate sulphur amino acid
catabolism (Table 4). CKD had no statistically signifi-
cant impact on the expression of CDO or CSAD
mRNA (Table 4), but did up-regulate expression of
the mRNA encoding taurine transporters GAT2 and
TauT (Table 4).
In contrast, when expression of CSAD protein was
assessed by immunoblotting in the livers of the NxC
group of CKD rats, this showed a clear decrease to 45%
of the value in sham operated control animals (S) (Fig.
1a, b), consistent with the reduction in the taurine flux
into urine in the NxC group (36% of the S value in Table
3) and the accompanying reduction in the urinary tau-
rine/ SO4
2− excretion ratio (36% of the S value in Table
3). Conversely, immunoblotting performed on plasma
detected an apparent increase in the CSAD protein sig-
nal (Fig. 1d). Specificity of the signal observed in the
CSAD immunoblots was confirmed by abolition of the
signal (both in liver (Fig. 1e) and in plasma) on pre-
Fig. 1 Response of rat liver to CKD with (NxT) or without (NxC) dietary L-glutamine supplementation. S denotes sham-operated control rats. All
data refer to Day 14 (i.e. 28 days after surgery). Feeding of experimental diets was performed from Day 1 to Day 14. a Representative
immunoblots obtained from liver lysates using antibodies against P-JNK (dually phosphorylated (P-Thr183/P-Tyr185) JNK2); P-P38 (phosphorylated
(P-Thr180/P-Tyr182) P38 MAPK); Total P38 MAPK; β-Actin; CDO (cysteine dioxygenase); and CSAD (cysteine sulphinic acid decarboxylase). b
Quantification of blots from (a) by densitometry. c Colorimetric catalytic assay for alanine transaminase (ALT) in plasma. POS denotes reading
obtained with positive control provided in the assay kit. d Representative immunoblot obtained from blood plasma using antibody against CSAD,
with albumin as loading control (top panel) and quantification of blots by densitometry (bottom panel). e CSAD immunoblot showing the effect
of incubation with primary anti-CSAD antibody as in (a) (top panel); or overnight pre-incubation of primary antibody with antigenic blocking
peptide [C]-SLRGKKESPDYSQRLS-amide at 10 μg/ml (bottom panel). Data are presented as Mean ± SEM, n = 8 rats in each group. *P < 0.05
versus Sham
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incubating the primary antibody with the specific CSAD
blocking peptide. Probing for expression of CDO protein
in the same livers detected no change in response to
CKD (Fig. 1a).
Impact of L-glutamine on taurine in this CKD model
In spite of the previously reported increase in plasma
taurine concentration induced by L-glutamine in rats
with intact renal function [21], dietary supplementation
with L-glutamine failed to increase the taurine concen-
tration in plasma in the present CKD model (Table 3),
nor did it normalise the taurine / SO4
2− ratio in urine
(Table 3), or the CSAD protein expression in liver (Fig.
1a, b). Indeed the mean level of expression of CSAD
mRNA seemed lower in the L-glutamine supplemented
NxT group than in S and NxC (relative expression
0.33 ± 0.13 for NxT in Table 4), but this was not statisti-
cally significant.
Discussion
Characterisation of the CKD model and L-glutamine
supplementation
In good agreement with earlier characterisation of
this surgical model of CKD [23], the partially
nephrectomised rats in groups NxC and NxT in the
present study showed reduced GFR and moderate
azotemia when compared with the sham-operated
control animals (Table 2). In spite of failure to detect
an increase in the plasma or tissue L-glutamine con-
centration in the L-glutamine supplemented NxT
group (Table 3), there was good evidence for catabol-
ism of the ingested L-glutamine resulting in enhanced
urea excretion and consequently urea-induced os-
motic diuresis (Table 2) which has previously been
reported as a consequence of enhanced urea produc-
tion in rats [30]. In spite of this, no significant ana-
bolic effect of L-glutamine was observed (Table 2),
indeed the 14 day body weight gain was lower in the
NxT rats compared with the NxC group, possibly as
a consequence of diuresis. Furthermore, in spite of
the increased ureagenesis in the NxT rats, no signifi-
cant increase in residual renal mass was observed in
comparison with the NxC group (Table 2) in contrast
with the urea-induced renal hypertrophy that has pre-
viously been reported in urea-supplemented rats with
intact kidneys [30].
Evidence of defective taurine metabolism
The main strength of the present study is that it is the
first to demonstrate by direct measurements in a rat
model of CKD the hepatic depletion of CSAD, a key en-
zyme of taurine biosynthesis, accompanied by a marked
reduction in the steady-state rate of appearance of tau-
rine in the animals’ urine and a decrease in the taurine/
sulphate excretion ratio (Fig. 1 and Table 3).
It has been suspected for more than 20 years that a
defect exists in the hepatic biosynthesis of taurine in
human patients with advanced CKD, both in pre-
dialysis patients [11] and in end-stage patients receiv-
ing dialysis [10, 11]. The steady-state rate of appear-
ance of taurine in the urine in the absence of dietary
taurine has previously been used as a measure of the
endogenous rate of taurine biosynthesis [31]. The de-
cline in taurine excretion rate in Table 3 in the
present study is therefore consistent with the im-
paired taurine biosynthesis arising from CSAD insuffi-
ciency that was previously proposed [10]. In liver,
CSAD is the enzyme that partitions the sulphur
amino acid flux between the pathway to taurine and
the alternative pathway to sulphurous and sulphuric
acid (which can be assessed by measuring sulphate
SO4
2− excretion [31]). If the previously proposed in-
sufficiency of CSAD in CKD [10] is occurring here,
the ratio of taurine generation to SO4
2− generation
would be expected to decrease. As predicted, this ra-
tio did indeed decrease in the NxC group compared
with the S group (Table 3), consistent with CSAD im-
pairment (probably in the liver [32]).
If the metabolic flux through CSAD is impaired in
the NxC group, a possible outcome is diversion of
Table 4 Effect of CKD and dietary L-glutamine supplementation on expression of mRNAs encoding regulatory enzymes of taurine
biosynthesis and taurine transporters in rat liver on Day 14 (i.e. 28 days after surgery)
Sham-operated, on Control diet, S
(n = 8)
Partial nephrectomy, on Control diet, NxC
(n = 8)
Partial nephrectomy, on Test diet, NxT
(n = 8)
Liver
CSAD 1.19 ± 0.35 0.91 ± 0.18 0.33 ± 0.13
CDO 1.08 ± 0.20 0.87 ± 0.14 1.00 ± 0.14
TauT
(SLC6A6)
0.81 (0.64–0.90) 3.38 (1.86–4.33) 3.50 (1.71–15.14)*
GAT2
(SLC6A13)
0.95 (0.87–1.08) 2.16 (1.22–14.64) 22.7 (19.73–32.84)*
Feeding of experimental diets was performed from Day 1 to Day 14. Relative amounts of mRNA were normalized to the corresponding cyclophilin A signal for
each sample, and relative expression is presented as (2-ΔΔCT). Data are presented as Mean ± SEM or as Median (inter-quartile range). *P < 0.05 versus Sham
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the flux of sulphur down the alternative pathway to
SO4
2− resulting in increased 24 h excretion of SO4
2−
in the NxC group compared with the sham-operated
S group. This increase was not observed (Table 3)
and, as a consequence, the total rate of sulphur ex-
cretion (taurine plus SO4
2−) was lower in the NxC
group compared with the S group (Table 3). The fur-
ther observation that total taurine plus SO4
2− excre-
tion rate was 11% lower in the NxT group than in
the NxC group (Table 3) probably reflects the dis-
placement of dietary sulphur amino acids in each Kg
of diet by the 12% L-glutamine supplement.
Mechanism of defective taurine metabolism in CKD
In spite of the findings above, it is important to em-
phasise that a defect in hepatic biosynthesis is un-
likely to be the only abnormality in taurine
physiology in CKD, either in the current rat model
or in end-stage human CKD. The observation here
in the NxC rats of unaltered taurine concentration
in plasma, liver and muscle (Table 3) in spite of a
significant steady-state decline in the rate of appear-
ance of taurine in the urine demonstrated a marked
renal retention of taurine, with an 81% decrease in
taurine clearance. Much of this retention may be at-
tributable to the reduced GFR in this CKD model
(demonstrated by the accompanying 63% decrease in
creatinine clearance (Table 2)). Such taurine reten-
tion may explain why, in non-taurine supplemented
patients with end-stage renal failure, whose plasma
taurine concentration is clearly low [10, 11], subse-
quent moderate oral taurine supplementation results
in severe hypertaurinaemia that would not be ob-
served with this level of supplementation in healthy
individuals [20].
A further taurine abnormality observed here was that
in the NxT group there was significantly enhanced hep-
atic expression of genes encoding taurine transporters
TauT and GAT2 (Table 4) which perform inwardly di-
rected active transport of taurine in hepatocytes [33, 34].
Compensatory up-regulation of the transporters to re-
store intra-hepatocyte taurine concentration in the face
of CSAD insufficiency is a possible explanation. How-
ever, it should be noted that this gene expression effect
did not reach statistical significance in the clearly
CSAD-deficient NxC group (Table 4); and up-regulation
of TauT mRNA was not observed in CSAD knock-out
mice with normal renal function [15]. Uraemia may be a
contributor to this CKD-induced transporter upregula-
tion. This is supported by the fact that ureagenesis
(shown by the high 24 h urea excretion rate) and plasma
urea concentration in the NxT group were both twice as
high as in the NxC group (Table 2), and may explain
why the transporter up-regulation reached statistical
significance in the NxT group but not in the NxC group
(Table 4).
The observation here of a significant reduction in the
24 h flux of taurine into urine, implying impairment of
taurine biosynthesis, could in principle have arisen from
a decrease in the activity of additional enzymes other
than just CSAD; for example CDO, the other major en-
zyme (upstream of CSAD) that influences sulphur amino
acid catabolism in liver and hence the total rate of pro-
duction of taurine plus sulphate (SO4
2−) [13]. Even
though no significant decline in CDO expression at
mRNA level or at protein level was detected in the NxC
rats compared with the sham-operated control rats
(Table 4 and Fig. 1a), a decline in the metabolic flux
through CDO (possibly because of events upstream of
CDO) cannot be ruled out. The occurrence of such add-
itional effects of CKD (independent of CSAD) may ex-
plain why the total 24 h rate of taurine + sulphate (SO4
2
−) excretion into urine was 23% lower in the NxC CKD
group than in the sham-operated S group (Table 3).
Theoretically depletion of sulphur amino acid substrates
L-methionine and L-cysteine could have contributed to
this decrease, but no evidence for such depletion in NxC
versus S group rats was found in the plasma or tissue
amino acid pools that were detectable in Table 3. In-
deed, as in human skeletal muscle in an earlier report
[35], free L-cysteine was not routinely detectable in so-
leus and liver in the present study.
There was no evidence in this study of significant
transcriptional effects of CKD on CSAD expression in
the NxC rats (Table 4). It therefore seems unlikely
that the previously documented transcriptional regula-
tion of CSAD by bile acids [36] was significantly dis-
turbed here by the bile acid abnormalities that occur
in end-stage CKD [37]. However, it should not be
concluded from the present data that effects at
mRNA level play no role in the taurine metabolism
abnormalities described here. For example, even
though it was not statistically significant, the marked
downward trend in CSAD mRNA in the NxT group
merits further investigation and it would be of inter-
est in future work to examine the time course of
CSAD and CDO mRNA in CKD.
It remains to be determined whether CKD affects
post-transcriptional regulation of hepatic CSAD expres-
sion and whether this decreases the stability of the pro-
tein to proteolysis, or alters trafficking of the protein
within the cell (possibly to the extracellular compart-
ment – as implied by Fig. 1d). It has been reported that,
at least in brain, CSAD is phosphorylated, a post-
translational modification which activates the enzyme
[38]; and more recent studies have detected phosphoryl-
ation specifically at threonine residue 84 in human
CSAD [39]).
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Impact of L-glutamine supplementation
Even though the 14-day dietary L-glutamine supple-
ment was well tolerated by the partially nephrecto-
mised rats in this study, it yielded no obvious
benefits, either in terms of rectifying the taurine de-
fect or in terms of body composition. It also wors-
ened proteinuria and caused a significant increase in
urinary urea excretion. The resulting urea-induced os-
motic diuresis is clearly undesirable, not least because
this effect of urea has been reported to cause clinic-
ally significant hypernatraemia in humans [40].
Limitations of this study
An earlier study of the effect of L-glutamine supplemen-
tation in rats with intact renal function [21] reported an
increase in plasma L-glutamine and taurine concentra-
tion. Neither of these were observed in the present
study. This difference may have arisen because the
present study differs in two important respects from the
earlier one: firstly because of the presence of CKD; sec-
ondly because the control (non-L-glutamine supple-
mented) rats here were not given the iso-caloric iso-
nitrogenous load of control amino acids (comprising L-
asparagine, L-serine, glycine, L-proline, and L-alanine)
that was applied in the original study [21]. This change
was made here to allow the effect of L-glutamine’s ac-
companying calorie and nitrogen load to be assessed in
the CKD rats. Displacement of other nutrients in each
Kg of diet by the substantial mass of L-glutamine could
in principle have affected the taurine status of the CKD
rats. However, applying a heavy control load of non-L-
glutamine neutral amino acids (as in the earlier study
[21]) also risked confounding effects (e.g. by competitive
inhibition or down-regulation of L-methionine trans-
porters such as SNAT2/SLC38A2 which are regulated
by neutral amino acid load [41]). As sham control
groups receiving the test diet or the previously described
non-L-glutamine neutral amino acid load [21] were not
included in the present study, it was not possible to as-
sess the effect of L-glutamine supplementation or the
non-specific effects of other neutral amino acids on tau-
rine metabolism in the absence of CKD. In future work
such controls might be helpful to shed light on why L-
glutamine failed here to show the previously reported
[21] beneficial effects on taurine physiology.
A further limitation in this study was that no baseline
collection of urine data was obtained from the rats at
the start of the 14-day experimental period or before
surgery. In principle any initial mismatching in baseline
amino acid and sulphur metabolism between the groups
of animals might have contributed to the failure to ob-
serve here the previously reported effect of L-glutamine
supplementation on taurine metabolism. It is possible
therefore that some beneficial effects of L-glutamine
supplementation were overlooked in the present study
as a consequence of this.
Finally, even though a number of other metabolic de-
fects have been reported in liver in CKD [1–3], possibly
occurring through the P38 MAP kinase-mediated in-
flammatory injury that is observed in models of liver in-
jury [4–9], measurements of P38 and JNK MAP kinase
activation in the present study detected no statistically
significant activation of these kinases in the NxC rats
(Fig. 1a, b), nor did measurements of the LFT enzyme
ALT detect any abnormality (Fig. 1c). The mechanism
linking CKD to the taurine defects described in this
study therefore remains to be determined.
Implications of defective CSAD in CKD
This study is the first to report a substantial defect in
the enzyme CSAD (and hence in taurine metabolism) in
a pathological state (CKD) relevant to human disease.
As it has been reported that taurine may play a signifi-
cant role in prevention of endothelial and cardiovascular
dysfunction [17], at least partly through its potent
physiological [42] and anti-oxidant [16] effects, it is
likely that CSAD insufficiency in CKD has pathological
consequences, possibly contributing to the burden of
cardiovascular disease which is the major cause of death
[18] in CKD patients. This view is reinforced by evidence
from CSAD knock-out mice in which there was consid-
erable mortality in the mice accompanied by up-
regulation of genes encoding anti-oxidant enzymes [15],
indicating oxidative stress. Significant oxidative stress is
known to occur in the present partial nephrectomy CKD
model when it is extended to 12 weeks post-surgery [23].
In the present relatively short 14 day study, commencing
14 days post-surgery, renal retention of taurine main-
tained the taurine pool size in the CKD model (Table 3)
in spite of the CSAD depletion, but long-term taurine
depletion is known to occur in advanced human CKD
[10, 11] implying that the taurine retention effect ob-
served here has limited duration. For this reason, further
work on the molecular basis of hepatic CSAD depletion
and long-term taurine abnormalities may be of value in
reducing the burden of oxidative stress and cardiovascu-
lar mortality which are of such importance in patients
with CKD.
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